3 Reasons Freespira Earned the 2020 Most Innovative Companies Designation
Freespira is proud to be recognized as one of the most innovative companies in healthcare. The prestigious honor is even more meaningful because Freespira was selected for the inaugural 2020 list by David Shulkin, M.D., the Ninth Secretary of the US Department of Veterans Affairs, who understands the struggles of millions of veterans living with PTSD.
“PTSD disrupts the daily lives of millions of Americans,” said Shulkin. “Yet, traditional medication and counseling therapies often fall short for these sufferers – many of whom have begun to believe that there is no hope for relief or remission. Innovative drug-free approaches, like Freespira, that address the underlying physiological symptoms of PTSD provide a new solution – and new hope – to this problem.”
Here’s why Shulkin chose Freespira for the list:
- New approaches like Freespira have never been more critical: Freespira’s earned a much-coveted spot on the list in the increasingly crowded behavioral health space – a category which took on increased importance in 2020 because the nation’s mental health crisis has been exacerbated by the stresses of COVID-19. New approaches to addressing behavioral health issues, like Freespira, are exploding, as more patients than ever before are in need of help – and traditional methods like therapy or ongoing medication often can’t provide relief.
- Freespira has already been proven effective at the Veterans Administration: A clinical trial conducted at the VA Palo Alto Health Care System in Palo Alto, Calif. demonstrated the efficacy of Freespira for veterans and non-veterans suffering from PTSD. Eighty-five percent of the subjects experienced significant reductions in measures of PTSD severity post-treatment. In addition, half of the veteran subjects reported remission scores six months post-treatment.
- Freespira tackles panic disorder and PTSD differently: Freespira is a one-time investment that can eliminate panic attacks and PTSD symptoms long after treatment ends. The first FDA-cleared digital therapeutic significantly reduces or eliminates symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 day by training users to normalize respiratory irregularities.